KR950701520A - 셀레노아미노산의 경피적용에 의한 외인성 피부노화의 재생법(Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids)) - Google Patents

셀레노아미노산의 경피적용에 의한 외인성 피부노화의 재생법(Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids))

Info

Publication number
KR950701520A
KR950701520A KR1019940704132A KR19940704132A KR950701520A KR 950701520 A KR950701520 A KR 950701520A KR 1019940704132 A KR1019940704132 A KR 1019940704132A KR 19940704132 A KR19940704132 A KR 19940704132A KR 950701520 A KR950701520 A KR 950701520A
Authority
KR
South Korea
Prior art keywords
selenomethionine
skin
composition
concentration
weight
Prior art date
Application number
KR1019940704132A
Other languages
English (en)
Other versions
KR100339915B1 (ko
Inventor
이. 버크 카렌
Original Assignee
이. 버크 카렌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이. 버크 카렌 filed Critical 이. 버크 카렌
Publication of KR950701520A publication Critical patent/KR950701520A/ko
Application granted granted Critical
Publication of KR100339915B1 publication Critical patent/KR100339915B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 피부 세포 및 분자의 만성적인 손상의 복원을 증진시키고 촉진시키는 방법을 제공한다. 또한 본 발명은 외인성 자유라디칼에 의해 농후화된 포유동물, 바람직하게는 사람 피부의 각질층을 박층화시키고 외인성 자유라디칼에 의해 손상된 탄력조직을 회복시키는 방법을 제공한다. 이러한 방법은 약제학적으로 허용되는 경피담체중에 셀레노아미노산을 함유하는 조성물을 포유동물, 바람직하게는 사람의 피부에 국소 투여함을 포함한다.

Description

셀레노아미노산의 경피작용에 의한 외인성 피부노화의 재생법(Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 필수적으로 약제학적으로 허용되는 경피담체중의 셀레노아미노산으로 이루어진 조성물을 피부에 국소투여함을 포함하여, 포유동물 피부세포 및 분자의 만성적인 손상의 복원을 증진시키고 촉진시키는 방법.
  2. 제1항에 있어서, 셀레노아미노산이 L-셀레노메티오닌인 방법.
  3. 제1항에 있어서, 셀레노메티오닌이 조성물의 총중량을 기준으로 0.002중량%이상의 농도로 존재하는 방법
  4. 제1항에 있어서, 셀레노메티오닌의 농도가 0.02중량%내지 0.1중량%인 방법.
  5. 제1항에 있어서, 셀레노메티오닌의 농도가 약0.5중량%인 방법.
  6. 제1항에 있어서, 조성물을 2개월 이상동안 주당 5회이상으로 투여하는 방법.
  7. 제1항에 있어서, 손상이 환경요인에 의해 생성되는 방법.
  8. 제1항에 있어서, 환경요인이 자외선 조사 및 환경오염인 방법.
  9. 제1항에 있어서, 손상이 광노화인 방법.
  10. 제1항에 있어서, 경피 담체가 환경요인에 의해 손상된 피부의 세포, 분자 또는 기질성분에 셀레노아미노산을 경피 운반하는 방법.
  11. 제1항에 있어서, 조성물이 추가로 카로덴, 레티노이드 또는 토코페롤의 이성체 또는 이의 에스테르 유도체를 함유하는 방법.
  12. 필수적으로 약제학적으로 허용되는 경피담체중의 셀레노아미노산으로 이루어진 조성물을 포유동물의 피부에 국소투여함을 포함하여, 외인성 자유 라디칼에 의해 농후화된 포유동물 피부의 각질층을 박층화시키고 외인성 자유 라디칼에 의해 손상된 탄력조직을 회복시키는 방법.
  13. 제12항에 있어서, 셀레노아미노산이 L-셀레노메티오닌인 방법.
  14. 제12항에 있어서, 셀레노메티오닌이 조성물의 총중량을 기준으로 0.002중량%이상의 농도로 존재하는 방법
  15. 제12항에 있어서, 셀레노메티오닌의 농도가 0.02중량% 내지 0.1중량%인 방법.
  16. 제12항에 있어서, 셀레노메티오닌의 농도가 약0.5중량%인 방법.
  17. 제12항에 있어서, 조성물을 2개월 이상동안 주당 5회이상으로 투여하는 방법.
  18. 제12항에 있어서, 고성물이 추가로 카로덴, 레티노이드 또는 토코페롤의 이성체 또는 이의 에스테르 유도체를 함유하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940704132A 1992-05-20 1993-05-19 셀레노아미노산의경피적용에의한외인성피부노화의재생법 KR100339915B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88650192A 1992-05-20 1992-05-20
US07/886501 1992-05-20
US07/886,501 1992-05-20
PCT/US1993/004780 WO1993023030A1 (en) 1992-05-20 1993-05-19 Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids

Publications (2)

Publication Number Publication Date
KR950701520A true KR950701520A (ko) 1995-04-28
KR100339915B1 KR100339915B1 (ko) 2002-11-23

Family

ID=25389139

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704132A KR100339915B1 (ko) 1992-05-20 1993-05-19 셀레노아미노산의경피적용에의한외인성피부노화의재생법

Country Status (12)

Country Link
US (1) US5330757A (ko)
EP (1) EP0641201B1 (ko)
JP (1) JP3550149B2 (ko)
KR (1) KR100339915B1 (ko)
AT (1) ATE195253T1 (ko)
AU (1) AU670298B2 (ko)
CA (1) CA2136238C (ko)
DE (1) DE69329198T2 (ko)
DK (1) DK0641201T3 (ko)
PT (1) PT641201E (ko)
SG (1) SG52678A1 (ko)
WO (1) WO1993023030A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014822A1 (en) * 1994-11-15 1996-05-23 Osmotics Corporation Skin care compositions and methods
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
US6138683A (en) * 1997-09-19 2000-10-31 Thione International, Inc. Smokeless tobacco products containing antioxidants
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
FR2873026B1 (fr) * 2004-07-13 2009-10-30 Oreal Procede de traitement cosmetique pour prevenir ou retarder les signes du vieillissement
AU2012237327B2 (en) 2011-04-01 2016-10-20 Iasomai Ab New combination comprising N-acetyl-L-cysteine and its use
WO2021140417A2 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137209A (en) * 1977-11-14 1979-01-30 Owens-Corning Fiberglas Corporation Glass fiber size composition
US4271229A (en) * 1979-09-04 1981-06-02 Ppg Industries, Inc. Sizing composition to yield sized glass fibers with improved UV stability
US4382991A (en) * 1979-09-04 1983-05-10 Ppg Industries, Inc. Sizing composition and sized strand useful as reinforcement
JPS57165420A (en) * 1981-04-07 1982-10-12 Seiko Kagaku Kogyo Co Ltd Production of water-dispersed urethane polymer
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
JPS63222050A (ja) * 1987-03-10 1988-09-14 Nippon Sheet Glass Co Ltd 樹脂で被覆されたガラス繊維
US4865840A (en) * 1987-04-29 1989-09-12 Burke Karen E Topical compositions containing selenoamino acids for the prevention of ultraviolet radiation-induced skin damage
JPH05117126A (ja) * 1991-10-25 1993-05-14 Pola Chem Ind Inc 化粧料

Also Published As

Publication number Publication date
SG52678A1 (en) 1998-09-28
JP3550149B2 (ja) 2004-08-04
DE69329198T2 (de) 2001-05-17
CA2136238C (en) 2004-08-10
AU4383893A (en) 1993-12-13
DK0641201T3 (da) 2000-12-27
US5330757A (en) 1994-07-19
EP0641201B1 (en) 2000-08-09
JPH07508040A (ja) 1995-09-07
EP0641201A4 (en) 1995-05-17
KR100339915B1 (ko) 2002-11-23
WO1993023030A1 (en) 1993-11-25
ATE195253T1 (de) 2000-08-15
DE69329198D1 (de) 2000-09-14
CA2136238A1 (en) 1993-11-25
EP0641201A1 (en) 1995-03-08
PT641201E (pt) 2001-01-31
AU670298B2 (en) 1996-07-11

Similar Documents

Publication Publication Date Title
CA1329553C (en) Pharmaceutical preparations
US5574063A (en) Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
US6472432B1 (en) Treatment of rosacea using lipoic acid
US5122536A (en) Method for the topical treatment of psoriasis
AU686123B2 (en) Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
AR011673A1 (es) Una composicion que comprende un ingrediente beneficioso cosmetico y un metodo cosmetico, que excluye todo tratamiento terapeutico, para reducir el escozor o la irritacion.
ATE180975T1 (de) Topische arzneiformen mit insulin
ATE99928T1 (de) Ester des retinols und/oder der retinsaeure enthaltende aerosol-inhalate.
ES2093747T3 (es) Composicion farmaceutica que contiene felbinac.
KR880009662A (ko) Igf-ii함유 약제
ES2184836T3 (es) Composiciones que contienen derivados de azol para aplicacion topica en la piel.
AR019823A1 (es) Una composicion cosmetica para el cuidado de la piel y un metodo para reducir la irritacion o el picor de la piel
PT92905A (pt) Processo para a preparacao de composicoes farmaceuticas para o tratamento da pele contendo retinodes
US20040265345A1 (en) Treatment of skin damage using acetyl carnitine and lipoic acid
KR950701520A (ko) 셀레노아미노산의 경피적용에 의한 외인성 피부노화의 재생법(Renewal of extrinsic aging of the skin by transdermal application of selenoamino acids))
ATE183075T1 (de) Retinoid enthaltendes mittel
US7438896B2 (en) Method of skin care using lipoic and ascorbic acids
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
US6752999B2 (en) Method of skin care and/or treatment using lipoic acid
EP1977743B1 (en) Compositions containing retinoid and beta-aminoisobutyric acid derivates
BR9002240A (pt) Processo para a preparacao de uma composicao conservada apropriada para aplicacao topica a pele e composicao
Kim et al. Effects of tretinoin pretreatment on TCA chemical peel in guinea pig skin
Birnbaum Retinoic acid-induced psoriasiform lesions in guinea pigs: antagonism by anti-psoriasis agents
Fuchs et al. Vitamin E in dermatological therapy
RU95109228A (ru) Способ лечения трофических язв

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070423

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee